Intensive Care Medicine

, 35:1859 | Cite as

Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients

  • Caroline Guignant
  • Nicolas Voirin
  • Fabienne Venet
  • Françoise Poitevin
  • Christophe Malcus
  • Julien Bohé
  • Alain Lepape
  • Guillaume MonneretEmail author



Improvements in survival after septic shock will most likely rely on our capacity to manage individualized therapies based on the measurement of rapidly accessible biomarkers. As the early phase of septic shock is dominated by severe alterations of the cardiovascular system, the predictive value for mortality of pro-vasopressin (pro-AVP) and pro-adrenomedullin (pro-ADM), two vasoactive pro-hormones, was assessed.


In 99 consecutive patients, pro-hormone concentrations were measured (immunoluminometric assay) three times within the first week after the onset of septic shock.


Pro-AVP and pro-ADM concentrations were significantly increased in non-survivors in comparison with survivors and were significantly associated with mortality after both univariate and multivariate analysis. Importantly, when assessed as a pair, pro-ADM and pro-AVP were even more informative.


Both Pro-ADM and pro-AVP appear to be good biomarkers for the prediction of 28-day mortality after septic shock. However, their association in a single variable tends to improve their predictive capacity.


Septic shock Mortality Prognosis Adrenomedullin Vasopressin 



This work was supported by the Hospices Civils de Lyon and was conducted thanks to the support of Brahms—we especially thank Dr. N.G. Morgenthaler and Dr. A. Bergmann. All measurements were performed in the Research Department of Brahms AG in a totally blinded fashion without knowledge of clinical parameters. This work was also conducted thanks to the logistical support (H. Thizy, F. Gueyffier) from the Centre d’Investigation Clinique (CIC 201) de Lyon (Clinical Research Centre) of INSERM and Hospices Civils de Lyon.

Supplementary material

134_2009_1610_MOESM1_ESM.doc (90 kb)
Table S1 (DOC 90 kb)


  1. 1.
    Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 9:1303–1310CrossRefGoogle Scholar
  2. 2.
    Dombrovskiy VY, Martin AA, Sunderram J, Paz HL (2007) Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 35:1244–1250CrossRefPubMedGoogle Scholar
  3. 3.
    Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365:63–78CrossRefPubMedGoogle Scholar
  4. 4.
    Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J M 348:138–150CrossRefGoogle Scholar
  5. 5.
    Carlet J, Cohen J, Calandra T, Opal SM, Masur H (2008) Sepsis: time to reconsider the concept. Crit Care Med 36:964–966CrossRefPubMedGoogle Scholar
  6. 6.
    Marshall JC (2008) Sepsis: rethinking the approach to clinical research. J Leukoc Biol 83:471–482CrossRefPubMedGoogle Scholar
  7. 7.
    Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, Heard SO, Martin C, Napolitano LM, Susla GM, Totaro R, Vincent JL, Zanotti-Cavazzoni S (2004) Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 32:1928–1948CrossRefPubMedGoogle Scholar
  8. 8.
    Flierl MA, Rittirsch D, Huber-Lang MS, Sarma JV, Ward PA (2008) Molecular events in the cardiomyopathy of sepsis. Mol Med 14:327–336PubMedGoogle Scholar
  9. 9.
    Matsuda N, Hattori Y (2007) Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res 43:117–137CrossRefPubMedGoogle Scholar
  10. 10.
    Treschan TA, Peters J (2006) The vasopressin system: physiology and clinical strategies. Anesthesiology 105:599–612CrossRefPubMedGoogle Scholar
  11. 11.
    Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D (2003) Circulating vasopressin levels in septic shock. Crit Care Med 31:1752–1758CrossRefPubMedGoogle Scholar
  12. 12.
    Hinson JP, Kapas S, Smith DM (2000) Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 21:138–167CrossRefPubMedGoogle Scholar
  13. 13.
    Zudaire E, Portal-Núñez S, Cuttitta F (2006) The central role of adrenomedullin in host defense. J Leukoc Biol 80:237–244CrossRefPubMedGoogle Scholar
  14. 14.
    Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M (2007) Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 28:219–226CrossRefPubMedGoogle Scholar
  15. 15.
    Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B (2005) Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 9:R816–R824CrossRefPubMedGoogle Scholar
  16. 16.
    Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ (2008) Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 12:R11CrossRefPubMedGoogle Scholar
  17. 17.
    Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S, Tamm M, Struck J, Bergmann A, Müller B (2006) Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care 10:R96CrossRefPubMedGoogle Scholar
  18. 18.
    Masiá M, Papassotiriou J, Morgenthaler NG, Hernández I, Shum C, Gutiérrez F (2007) Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 53:2193–2201CrossRefPubMedGoogle Scholar
  19. 19.
    Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, Bergmann A, Tamm M, Christ-Crain M (2007) Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 37:145–152CrossRefPubMedGoogle Scholar
  20. 20.
    Krüger S, Papassotiriou J, Marre R, Richter K, Schumann C, von Baum H, Morgenthaler NG, Suttorp N, Welte T, CAPNETZ Study Group (2007) CAPNETZ Study Group: pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med 33:2069–2078CrossRefPubMedGoogle Scholar
  21. 21.
    Bone RC (1992) Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 268:3452–3455CrossRefPubMedGoogle Scholar
  22. 22.
    Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard AL, Thizy H, Bienvenu J, Gueyffier F, Vanhems P (2006) Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 32:1175–1183CrossRefPubMedGoogle Scholar
  23. 23.
    McCabe WR, Jackson GC (1962) Gram-negative bacteremia. Arch Intern Med 110:847–864Google Scholar
  24. 24.
    Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963CrossRefPubMedGoogle Scholar
  25. 25.
    Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 26:1793–1800PubMedGoogle Scholar
  26. 26.
    Morgenthaler NG, Struck J, Alonso C, Bergmann A (2005) Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 51:1823–1829CrossRefPubMedGoogle Scholar
  27. 27.
    Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112–119CrossRefPubMedGoogle Scholar
  28. 28.
    Schuetz P, Christ-Crain M, Morgenthaler NG, Struck J, Bergmann A, Müller B (2007) Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 14:345–351CrossRefPubMedGoogle Scholar
  29. 29.
    Khan SQ, Dhillon O, Struck J, Quinn P, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL (2007) C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester acute myocardial infarction peptide (LAMP) study. Am Heart J 154:736–742CrossRefPubMedGoogle Scholar
  30. 30.
    Khan SQ, O’Brien RJ, Struck J, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL (2007) Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester acute myocardial infarction peptide) study. J Am Coll Cardiol 49:1525–1532CrossRefPubMedGoogle Scholar
  31. 31.
    Khan SQ, Dhillon OS, O’Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL (2007) C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester acute myocardial infarction peptide (LAMP) study. Circulation 115:2103–2110CrossRefPubMedGoogle Scholar
  32. 32.
    de Kruif MD, Lemaire LC, Giebelen IA, Struck J, Morgenthaler NG, Papassotiriou J, Elliott PJ, van der Poll T (2008) The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 34:518–522CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Caroline Guignant
    • 1
  • Nicolas Voirin
    • 2
  • Fabienne Venet
    • 1
  • Françoise Poitevin
    • 1
  • Christophe Malcus
    • 1
  • Julien Bohé
    • 3
  • Alain Lepape
    • 3
  • Guillaume Monneret
    • 1
    Email author
  1. 1.Flow Cytometry Unit, Immunology Laboratory, Hôpital E. Herriot, Hospices Civils de LyonLyon cedex 03France
  2. 2.INSERM U271, Hospices Civils de Lyon, Hôpital E. Herriot, Service d’Hygiène, Epidémiologie et PréventionUniversité de LyonLyonFrance
  3. 3.Intensive Care Units, Hospices Civils de Lyon, CH Lyon-SudLyonFrance

Personalised recommendations